Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The 1/4/6x24 campaign to cure tuberculosis quickly

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. United Nations General Assembly. Universal Declaration of Human Rights 217 A (III); (1948).

  2. United Nations General Assembly. International Covenant on Economic, Social and Cultural Rights 2200A (XXI); (1966).

  3. Swindells, S. et al. N. Engl. J. Med. 380, 1001–1011 (2019).

    Article  CAS  Google Scholar 

  4. Sterling, T. R. et al. N. Engl. J. Med. 365, 2155–2166 (2011).

    Article  CAS  Google Scholar 

  5. Dorman, S. E. et al. N. Engl. J. Med. 384, 1705–1718 (2021).

    Article  CAS  Google Scholar 

  6. Turkova, A. et al. N. Engl. J. Med. 386, 911–922 (2022).

    Article  CAS  Google Scholar 

  7. Conradie, F. et al. N. Engl. J. Med. 387, 810–823 (2022).

    Article  CAS  Google Scholar 

  8. Nyang’wa, B. T. et al. N. Engl. J. Med. 387, 2331–2343 (2022).

  9. Farmer, P. Am. J. Pub. Health 89, 1486–1496 (1999).

    Article  CAS  Google Scholar 

  10. Farmer, P. E. N. Engl. J. Med. 369, 2424–2436 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Lindsay McKenna.

Ethics declarations

Competing interests

J.F. received grant funding from the Stop TB Partnership’s Global Drug Facility to support the rollout of child-friendly formulations of second-line drugs. M.P. has no financial or industry conflicts to disclose; he serves as an advisor to the WHO, Foundation for Innovative New Diagnostics, Stop TB Partnership and Bill & Melinda Gates Foundation. B.-T.N. is employed by Médecins Sans Frontières, the sponsor of the TB-PRACTECAL trial that developed a 6-month multidrug-resistant/rifampicin-resistant TB (RR-/MDR-TB) regimen. Through grants to her institution, C.D.M. receives research funding to study all-oral shortened regimens for treatment of drug-resistant TB containing bedaquiline, delamanid, linezolid, clofazimine, levofloxacin, moxifloxacin and pyrazinamide.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McKenna, L., Frick, M., Angami, K. et al. The 1/4/6x24 campaign to cure tuberculosis quickly. Nat Med 29, 16–17 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing